X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with Sterling Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs STERLING BIOTECH - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

STERLING BIOTECH 
   Change

Sterling Biotech primarily produces and distributes pharmaceutical grade gelatine globally. The company currently has a 7.5% share of the global market for pharmaceutical and nutraceutical gelatines. It has more than 70% market share in India. Sterli... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA STERLING BIOTECH GSK PHARMA/
STERLING BIOTECH
 
P/E (TTM) x 65.0 -1.9 - View Chart
P/BV x 10.4 0.1 14,116.8% View Chart
Dividend Yield % 1.2 0.0 -  

Financials

 GSK PHARMA   STERLING BIOTECH
EQUITY SHARE DATA
    GSK PHARMA
Mar-17
STERLING BIOTECH
Dec-13
GSK PHARMA/
STERLING BIOTECH
5-Yr Chart
Click to enlarge
High Rs3,83811 36,552.4%   
Low Rs2,6373 77,558.8%   
Sales per share (Unadj.) Rs354.226.8 1,321.3%  
Earnings per share (Unadj.) Rs39.8-15.0 -265.9%  
Cash flow per share (Unadj.) Rs42.9-5.5 -784.8%  
Dividends per share (Unadj.) Rs30.000-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs236.954.9 431.7%  
Shares outstanding (eoy) m84.70267.87 31.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x9.10.3 3,525.6%   
Avg P/E ratio x81.4-0.5 -17,521.7%  
P/CF ratio (eoy) x75.5-1.3 -5,936.0%  
Price / Book Value ratio x13.70.1 10,790.0%  
Dividend payout %75.40-   
Avg Mkt Cap Rs m274,2161,862 14,729.4%   
No. of employees `0004.71.4 346.9%   
Total wages/salary Rs m4,830547 883.3%   
Avg. sales/employee Rs Th6,387.05,303.3 120.4%   
Avg. wages/employee Rs Th1,028.3403.8 254.6%   
Avg. net profit/employee Rs Th717.1-2,959.0 -24.2%   
INCOME DATA
Net Sales Rs m30,0007,181 417.8%  
Other income Rs m72843 1,709.4%   
Total revenues Rs m30,7287,223 425.4%   
Gross profit Rs m4,190947 442.5%  
Depreciation Rs m2632,543 10.3%   
Interest Rs m04,377 0.0%   
Profit before tax Rs m4,655-5,931 -78.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m4570-   
Tax Rs m1,744-1,924 -90.6%   
Profit after tax Rs m3,368-4,007 -84.1%  
Gross profit margin %14.013.2 105.9%  
Effective tax rate %37.532.4 115.5%   
Net profit margin %11.2-55.8 -20.1%  
BALANCE SHEET DATA
Current assets Rs m16,74214,335 116.8%   
Current liabilities Rs m7,20249,809 14.5%   
Net working cap to sales %31.8-494.0 -6.4%  
Current ratio x2.30.3 807.7%  
Inventory Days Days52403 12.8%  
Debtors Days Days21171 12.2%  
Net fixed assets Rs m8,63555,432 15.6%   
Share capital Rs m847268 316.2%   
"Free" reserves Rs m19,22213,935 137.9%   
Net worth Rs m20,06914,701 136.5%   
Long term debt Rs m109,478 0.1%   
Total assets Rs m30,03873,988 40.6%  
Interest coverage xNM-0.4-  
Debt to equity ratio x00.6 0.1%  
Sales to assets ratio x1.00.1 1,029.1%   
Return on assets %11.20.5 2,238.5%  
Return on equity %16.8-27.3 -61.6%  
Return on capital %25.5-6.4 -396.2%  
Exports to sales %025.9 0.0%   
Imports to sales %00.2 0.0%   
Exports (fob) Rs mNA1,860 0.0%   
Imports (cif) Rs mNA12 0.0%   
Fx inflow Rs m5281,860 28.4%   
Fx outflow Rs m7,19325 28,899.2%   
Net fx Rs m-6,6651,835 -363.2%   
CASH FLOW
From Operations Rs m2,3601,719 137.3%  
From Investments Rs m3,008-3,148 -95.5%  
From Financial Activity Rs m-5,1081,426 -358.2%  
Net Cashflow Rs m260-3 -7,655.9%  

Share Holding

Indian Promoters % 0.0 33.9 -  
Foreign collaborators % 50.7 0.0 -  
Indian inst/Mut Fund % 10.2 0.0 -  
FIIs % 23.8 9.9 240.4%  
ADR/GDR % 0.0 16.9 -  
Free float % 15.4 39.3 39.2%  
Shareholders   102,036 21,482 475.0%  
Pledged promoter(s) holding % 0.0 55.9 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   MERCK LTD  IPCA LABS  JUBILANT LIFE SCIENCES  VENUS REMEDIES  CIPLA  

Compare GSK PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Above 35,000 Mark; Bank & IT Stocks Outperform(Closing)

After opening the day flat, share markets in India witnessed positive trading activity throughout the day and ended the day on a strong note.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Is it Wise to Ignore Bitcoins?(The 5 Minute Wrapup)

Jan 4, 2018

While investing in bitcoins, it would make sense to treat it as another asset class and decide accordingly.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Resolutions for 2018 - by others(The Honest Truth)

Jan 8, 2018

Ten quirky new year resolutions. Guess by whom?

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Jan 17, 2018 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - SUN PHARMA COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS